Janssen's response to TB CAB letter regarding pharmacokinetic studies, paediatric studies, and compassionate use of bedaquiline.

WHO is working with countries to identify opportunities for expansion of treatment in line with its 2010 guidelines, which recommended treatment for all people living with HIV with CD4 cell counts below 350, all infants below the age of 2, and for everyone with TB and HIV or hepatitis B and HIV coinfection.

Russia currently ranks third by the number of multidrug-resistant TB cases worldwide after China and India, countries with vastly larger populations.

The investigational drug delamanid may help combat multidrug-resistant tuberculosis, results of a phase II trial indicate.

All HIV-positive TB patients, with immediate effect, are initiated on ART, irrespective of CD4 count.

Open letters to Otsuka, Janssen Pharmaceutical Companies of Johnson & Johnson, Food and Drug Administration and European Medicines Agency.

Medical innovation is not delivering for the needs of people in developing countries. 65th World Health Assembly to debate binding convention on R&D.

Tuberculosis is still one of the most important causes of death worldwide. Perseverance and renewed commitment are needed to achieve global control of tuberculosis, and ultimately, its elimination.

As of the end of the first quarter of 2012, nearly 864,000 GeneXpert MTB/RIF rapid tuberculosis (TB) diagnostic cartridges had been procured under manufacturer Cephied’s concessional pricing mechanism.

Between 1990 and 2010, in countries with tuberculosis (TB) programs supported by USAID, TB death rates decreased by 29 percent, and TB prevalence rates declined by 14 percent.